Product Description
Angiotensin II is the main effector molecule of the RAS. It causes increases in blood pressure, influences renal tubuli to retain sodium and water, and stimulates aldosterone release from adrenal gland. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3377325/)
Mechanisms of Action: AT1 Agonist,AT2 Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Netherlands | Norway | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | Sweden | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Innoviva
Company Location: BURLINGAME CA 94010
Company CEO: Pavel Raifeld
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Acute Kidney Injury|Liver Transplant|Other|Vasoplegia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TQG3902-III-01 | P3 |
Not yet recruiting |
Other |
2027-06-01 |
82% |
| AngLT-1 | P3 |
Recruiting |
Liver Transplant|Vasoplegia |
2025-09-01 |
|
| AIDED | P3 |
Active, not recruiting |
Acute Kidney Injury |
2022-05-16 |